Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study

Tomoyuki Goya, Hisao Asamura, Hirokuni Yoshimura, +6

Lung Cancer

Surgical OncologyMedicinePathologyBronchial NeoplasmCancer Registration +5

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer

Ken‐ichi Fujita, Wataru Yamamoto, Toshimichi Miya, +15

Cancer Chemotherapy and Pharmacology

Oncogenic AgentMedicinePharmacologyAbcb1 GenotypesPathology +7

Pharmacogenetic impact of polymorphisms in the coding region of the <i>UGT1A1</i> gene on SN‐38 glucuronidation in Japanese patients with cancer

Kazuhiro Araki, Ken‐ichi Fujita, Fumio Nagashima, +6

Cancer Science

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

Yasuhide Yamada, Makoto Tahara, Toshimichi Miya, +6

British Journal of Cancer

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38

Yasutsuna Sasaki, Hideo Hakusui, Shoichi Mizuno, +7

Japanese Journal of Cancer Research

<i>CYP2A6</i>and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1

Ken‐ichi Fujita, Wataru Yamamoto, Shoji Endo, +14

Cancer Science

A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy

Tetsu Shinkai, Kenji Eguchi, Yasutsuna Sasaki, +8

Cancer Chemotherapy and Pharmacology

MedicinePrognostic-factor Risk IndexPathologyBronchial NeoplasmCisplatin-containing Combination Chemotherapy +5

Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer

Ken‐ichi Fujita, Fumio Nagashima, Wataru Yamamoto, +6

Cancer Chemotherapy and Pharmacology

Cancer RiskGeneticsGenetic EpidemiologyHuman PolymorphismGenetic Linkage +6

Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11

Toshimichi Miya, Tomoyuki Goya, Hirofumi Fujii, +5

Investigational New Drugs

ObesityMetabolic SyndromeBody CompositionMedicineBody Mass Index +8

Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI)

Ken‐ichi Fujita, Fumio Nagashima, Wataru Yamamoto, +14

Biological and Pharmaceutical Bulletin